Angiotensin II receptor type 1 mRNA is unregulated in atria of patients with end stage heart failure

被引:13
|
作者
Kaprielian, RR [1 ]
Dupont, E [1 ]
Hafizi, S [1 ]
PooleWilson, PA [1 ]
Khaghani, A [1 ]
Yacoub, MH [1 ]
Sever, NJ [1 ]
机构
[1] HAREFIELD HOSP, HEART SCI CTR, HAREFIELD UB9 6BP, MIDDX, ENGLAND
关键词
heart failure; angiotensin II receptor; myocardium;
D O I
10.1006/jmcc.1997.0458
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is increasing evidence that pathological changes in the myocardium during chronic heart failure (CHF) are partly regulated through the activation of the renin-angiotensin system (RAS), an effect mediated by the angiotensin II type 1 receptor (AT(1)R), We examined the expression of cardiac AT(1)R mRNA in normal (atria, n=7: ventricle, n=3) and end-stage CHF human hearts (atria, n=8: ventricle, n=14). Tissue was snap-frozen immediately after explantation during orthotopic cardiac transplantation; control specimens were obtained from healthy donor hearts rejected for technical reasons. Northern blots of purified total mRNA from each tissue were hybridized with a random primed radiolabeled probe for the coding sequence of AT(1)R. Stringent conditions were used for both hybridization (5X SSC, 65 degrees C) and washing (0.5X SSC, 0.1% SDS, 65 degrees C) of the membrane, Left and right atrial tissue showed low levels of AT(1)R mRNA expression in the controls, with statistically significant upregulation of expression in tissue from pathological hearts; CHF atria 1.28+/-0.86 optical density (OD) units, control atria 0.56+/-0.31 OD units, P=0.05 (mean+/-S.D.). There were undetectable levels in ventricles from either control (2/2) or dilated hearts (7/7), The results were independent of the etiology of the heart failure and suggest that increased levels of atrial AT(1)R mRNA may occur in response to elevated atrial pressures in heart failure. (C) 1997 Academic Press Limited.
引用
收藏
页码:2299 / 2304
页数:6
相关论文
共 50 条
  • [21] Effects of chronic subdepressor dose of angiotensin II type 1 receptor antagonist on endothelium-dependent vasodilation in patients with congestive heart failure
    Nakamura, M
    Saito, S
    Yoshida, H
    Arakawa, N
    Sugawara, S
    Hiramori, K
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2002, 40 (03) : 411 - 419
  • [22] Angiotensin II type 1 and endothelin type A receptor antagonists modulate the extracellular matrix regulatory system differently in diastolic heart failure
    Yoshida, J
    Yamamoto, K
    Mano, T
    Sakata, Y
    Nishikawa, N
    Miwa, T
    Hori, M
    Masuyama, T
    JOURNAL OF HYPERTENSION, 2003, 21 (02) : 437 - 444
  • [23] Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure
    Liu, YH
    Xu, J
    Yang, XP
    Yang, F
    Shesely, E
    Carretero, OA
    HYPERTENSION, 2002, 39 (02) : 375 - 381
  • [24] Angiotensin II type 1 receptor blockers
    Burnier, M
    CIRCULATION, 2001, 103 (06) : 904 - 912
  • [25] Biased Agonism/Antagonism of Sartans and Angiotensin II Analogs for Angiotensin II Type 1 Receptor-Induced, β-Arrestin--Dependent Aldosterone Production in Heart Failure
    Lymperopoulos, Anastasios
    Rengo, Giuseppe
    Magafa, Vassiliki
    Cordopatis, Paul
    Koch, Walter J.
    CIRCULATION, 2010, 122 (21)
  • [26] Differential expression of type 1 angiotensin II receptor mRNA and aldosterone responsiveness to angiotensin in aldosterone-producing adenoma
    Chen, YM
    Wu, KD
    Hu-Tsai, MI
    Chu, JS
    Lai, MK
    Hsieh, BS
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1999, 152 (1-2) : 47 - 55
  • [27] Angiotensin II receptor subtypes in the skeletal muscle vasculature of patients with severe congestive heart failure
    Malendowicz, SL
    Ennezat, PV
    Testa, M
    Murray, L
    Sonnenblick, EH
    Evans, T
    LeJemtel, TH
    CIRCULATION, 2000, 102 (18) : 2210 - 2213
  • [28] Effects of angiotensin II type 1 receptor blockade in ApoE-deficient mice with post-ischemic heart failure
    Pons, S
    Hagège, A
    Fornes, P
    Gervais, M
    Giudicelli, JF
    Richer, C
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 42 (01) : 17 - 23
  • [29] The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure
    McKelvie, RS
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (03) : 245 - 253
  • [30] Hemodynamic and clinical effects of angiotensin II receptor antagonists in heart failure
    Dickstein K.
    Heart Failure Reviews, 1999, 3 (3) : 209 - 216